Announcements Trials
Browse Landscape

Phase

Phase 1/2 7Phase 2 4Phase 1 4Phase EARLY_PHASE1 1

Status

Completed 78Terminated 37Recruiting 31Active not recruiting 27Unknown 24Not yet recruiting 7Withdrawn 4

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 3Neoplasm Metastasis 1Estrogen Receptor Positive 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Fulvestrant × Clear all
NCT04901299 2023-08-01

HER2-Signal

Massachusetts General Hospital

Phase 2 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03377101 2018-08-14

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Breast

Estrogen Receptor Positive

NCT02140437 2015-12-29

Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC

Fudan University

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT02115594 2014-10-08

ENCORE305

Syndax Pharmaceuticals

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡